Autopsy report · NCT03048136

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

“Business objective has changed”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Bristol-Myers Squibb

Sponsor type

Industry

Conditions

Non-Small Cell Lung Cancer

Interventions

Nivolumab; Ipilimumab

Participants

0

Sites

17

Countries

Argentina, Canada, Germany, Peru, United States

Trials that died the same way

• Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
  “Business objectives have changed” (93% match in meaning)
• Entecavir Plus Adefovir in Lamivudine-Resistant Patients
  “Business Objectives Changed” (90% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (69% match in meaning)
• A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures
  “Change in business priorities.” (68% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.